Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 12, 2004. The report is a notification of changes in directors' interests in the company's Ordinary Shares, specifically regarding the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a retirement fund.
Material Changes
The primary material change reported is an increase in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan. As of October 8, 2004, the fund's holdings increased from 18,980,312 to 19,011,465 shares. This change occurred at an average price of $41.90 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that two directors, Dr. J.P. Garnier and Dr. T. Yamada, are potentially interested in the shares held in the fund as beneficiaries of the discretionary plan, similar to other employees.
Key Facts for Investor Verification
- The increase in ADR holdings was driven by a movement in the fund on October 8, 2004.
- The average transaction price for the fund movement was $41.90.
- Directors Dr. J.P. Garnier and Dr. T. Yamada have potential interests in the fund shares.
- No financial performance data is included in this specific filing.